Figure 3.

Effects of dolutegravir on neutrophil cytosolic Ca²⁺concentrations. Dolutegravir (Dol, 10 μg/mL) as denoted by the arrow (↓) was added to neutrophils suspended in Ca²⁺ -replete (-) and –depleted (- - - -) medium. An abrupt and sustained increase in cytosolic Ca²⁺ was observed following the addition of dolutegravir to the neutrophils suspended in Ca²⁺-replete HBSS, which was abolished in a Ca²⁺-free medium. The results of the entire series of experiments (16 separate experiments; n = 7 individual donors) are shown in the upper panel as the basal and peak cytosolic Ca²⁺ concentrations following the addition of dolutegravir to the neutrophils suspended in a Ca²⁺-replete medium and the basal Ca²⁺ concentration in the absence of extracellular Ca²⁺. Representative traces from a single experiment are shown in the lower panel. The tracing in the lower panel depicts a single experiment that is representative of those in the series of 9–16 replicates.